Higher infiltration of intratumoral CD25+ FOXP3+ lymphocytes correlates with a favorable prognosis in patients with diffuse large B-cell lymphoma

References

• Mohr A, Malhotra R, Mayer G, et al. Human FOXP3+ T regulatory cell heterogeneity. Clin Transl Immunol. 2018;7(1):e1005.
   PubMed Web of Science ®Google Scholar
• Tsurikisawa N, Saito H, Oshikata C, et al. An increase of CD83+ dendritic cells ex vivo correlates with increased regulatory T cells in patients with active eosinophilic granulomatosis and polyangiitis. BMC Immunol. 2014;15:32.
   PubMed Web of Science ®Google Scholar
• Miyara M, Yoshioka Y, Kitoh A, et al. Functional delineation and differentiation dynamics of human CD4+ T cells expressing the FoxP3 transcription factor. Immunity. 2009;30(6):899–911.
   PubMed Web of Science ®Google Scholar
• Ward-Hartstonge KA, Kemp RA. Regulatory T-cell heterogeneity and the cancer immune response. Clin Transl Immunol. 2017;6(9):e154.
   PubMedGoogle Scholar
• Cretney E, Kallies A, Nutt SL. Differentiation and function of Foxp3(+) effector regulatory T cells. Trends Immunol. 2013;34(2):74–80.
   PubMed Web of Science ®Google Scholar
• Vignali DA, Collison LW, Workman CJ. How regulatory T cells work. Nat Rev Immunol. 2008;8(7):523–532.
   PubMed Web of Science ®Google Scholar
• Kuwana M. Induction of anergic and regulatory T cells by plasmacytoid dendritic cells and other dendritic cell subsets. Hum Immunol. 2002;63(12):1156–1163.
   PubMed Web of Science ®Google Scholar
• Maldonado RA, von Andrian UH. How tolerogenic dendritic cells induce regulatory T cells. Adv Immunol. 2010;108:111–165.
   PubMed Web of Science ®Google Scholar
• Li S, Wu J, Zhu S, et al. Disease-associated plasmacytoid dendritic cells. Front Immunol. 2017;8:1268.
   PubMed Web of Science ®Google Scholar
• Yigit R, Massuger LF, Figdor CG, et al. Ovarian cancer creates a suppressive microenvironment to escape immune elimination. Gynecol Oncol. 2010;117(2):366–372.
   PubMed Web of Science ®Google Scholar
• Tanaka A, Sakaguchi S. Regulatory T cells in cancer immunotherapy. Cell Res. 2017;27(1):109–118.
   PubMed Web of Science ®Google Scholar
• Chang KC, Huang GC, Jones D, et al. Distribution patterns of dendritic cells and T cells in diffuse large B-cell lymphomas correlate with prognoses. Clin Cancer Res. 2007;13(22 Pt 1):6666–6672.
   PubMed Web of Science ®Google Scholar
• Chang KC, Huang GC, Jones D, et al. Distribution and prognosis of WHO lymphoma subtypes in Taiwan reveals a low incidence of germinal-center derived tumors. Leuk Lymphoma. 2004;45(7):1375–1384.
   PubMed Web of Science ®Google Scholar
• Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53(282):457–481.
   Web of Science ®Google Scholar
• Cox DR. Regression models and life tables. J R Stat Soc B. 1972;34(2):187–220.
   Google Scholar
• Cha Z, Gu H, Zang Y, et al. The prevalence and function of CD4 + CXCR5 + Foxp3+ follicular regulatory T cells in diffuse large B cell lymphoma. Int Immunopharmacol. 2018;61:132–139.
   PubMed Web of Science ®Google Scholar
• Rusak M, Bołkun Ł, Chociej-Stypułkowska J, et al. Flow-cytometry-based evaluation of peripheral blood lymphocytes in prognostication of newly diagnosed DLBCL patients. Blood Cells Mol Dis. 2016;59:92–96.
   PubMed Web of Science ®Google Scholar
• Głowala-Kosińska M, Chwieduk A, Nieckula J, et al. Association of circulating regulatory T cell number with the incidence and prognosis of diffuse large B-cell lymphoma. Eur J Haematol. 2013;91(2):122–128.
   PubMed Web of Science ®Google Scholar
• Felcht M, Heck M, Weiss C, et al. Expression of the T-cell regulatory marker FOXP3 in primary cutaneous large B-cell lymphoma tumour cells. Br J Dermatol. 2012;167(2):348–358.
   PubMed Web of Science ®Google Scholar
• Coutinho R, Clear AJ, Mazzola E, et al. Revisiting the immune microenvironment of diffuse large B-cell lymphoma using a tissue microarray and immunohistochemistry: robust semi-automated analysis reveals CD3 and FoxP3 as potential predictors of response to R-CHOP. Haematologica. 2015;100(3):363–369.
   PubMed Web of Science ®Google Scholar
• Lee NR, Song EK, Jang KY, et al. Prognostic impact of tumor infiltrating FOXP3 positive regulatory T cells in diffuse large B-cell lymphoma at diagnosis. Leuk Lymphoma. 2008;49(2):247–256.
   PubMed Web of Science ®Google Scholar
• Tzankov A, Meier C, Hirschmann P, et al. Correlation of high numbers of intratumoral FOXP3+ regulatory T cells with improved survival in germinal center-like diffuse large B-cell lymphoma, follicular lymphoma and classical Hodgkin's lymphoma. Haematologica. 2008;93(2):193–200.
   PubMed Web of Science ®Google Scholar
• Nam SJ, Kim S, Kwon D, et al. Prognostic implications of tumor-infiltrating macrophages, M2 macrophages, regulatory T-cells, and indoleamine 2,3-dioxygenase-positive cells in primary diffuse large B-cell lymphoma of the central nervous system. Oncoimmunology. 2018;7(7):e1442164.
   PubMed Web of Science ®Google Scholar
• Hasselblom S, Sigurdadottir M, Hansson U, et al. The number of tumour-infiltrating TIA-1+ cytotoxic T cells but not FOXP3+ regulatory T cells predicts outcome in diffuse large B-cell lymphoma. Br J Haematol. 2007;137(4):364–373.
   PubMed Web of Science ®Google Scholar
• Battella S, Cox MC, La Scaleia R, et al. Peripheral blood T cell alterations in newly diagnosed diffuse large B cell lymphoma patients and their long-term dynamics upon rituximab-based chemoimmunotherapy. Cancer Immunol Immunother. 2017;66(10):1295–1306.
   PubMed Web of Science ®Google Scholar
• Zhong W, Xu X, Zhu Z, et al. Increased interleukin-17A levels promote rituximab resistance by suppressing p53 expression and predict an unfavorable prognosis in patients with diffuse large B cell lymphoma. Int J Oncol. 2018;52(5):1528–1538.
   PubMed Web of Science ®Google Scholar
• Nakayama S, Yokote T, Akioka T, et al. Infiltration of effector regulatory T cells predicts poor prognosis of diffuse large B-cell lymphoma, not otherwise specified. Blood Adv. 2017;1(8):486–493.
   PubMed Web of Science ®Google Scholar
• Chang C, Wu SY, Kang YW, et al. High levels of regulatory T cells in blood are a poor prognostic factor in patients with diffuse large B-cell lymphoma. Am J Clin Pathol. 2015;144(6):935–944.
   PubMed Web of Science ®Google Scholar
• Grygorowicz MA, Biernacka M, Bujko M, et al. Human regulatory T cells suppress proliferation of B lymphoma cells. Leuk Lymphoma. 2016;57(8):1903–1920.
   PubMed Web of Science ®Google Scholar
• Lindqvist CA, Christiansson LH, Thorn I, et al. Both CD4+ FoxP3+ and CD4+ FoxP3– T cells from patients with B-cell malignancy express cytolytic markers and kill autologous leukaemic B cells in vitro. Immunology. 2011;133(3):296–306.
   PubMed Web of Science ®Google Scholar
• Gao Q, Qiu SJ, Fan J, et al. Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection. J Clin Oncol. 2007;25(18):2586–2593.
   PubMed Web of Science ®Google Scholar
• Kutzner H, Kerl H, Pfaltz MC, et al. CD123-positive plasmacytoid dendritic cells in primary cutaneous marginal zone B-cell lymphoma: diagnostic and pathogenetic implications. Am J Surg Pathol. 2009;33(9):1307–1313.
   PubMed Web of Science ®Google Scholar
• Uto T, Takagi H, Fukaya T, et al. Critical role of plasmacytoid dendritic cells in induction of oral tolerance. J Allergy Clin Immunol. 2018;141(6):2156–2167e9.
   PubMed Web of Science ®Google Scholar
• Schuster P, Lindner G, Thomann S, et al. Prospect of plasmacytoid dendritic cells in enhancing anti-tumor immunity of oncolytic herpes viruses. Cancers (Basel). 2019;11(5):651.
   Web of Science ®Google Scholar
• Gustafson MP, Lin Y, Maas ML, et al. A method for identification and analysis of non-overlapping myeloid immunophenotypes in humans. PLoS One. 2015;10(3):e0121546.
   PubMed Web of Science ®Google Scholar
• Khan ANH, Emmons TR, Wong JT, et al. Quantification of early-stage myeloid-derived suppressor cells in cancer requires excluding basophils. Cancer Immunol Res. 2020;8(6):819–828.
   PubMed Web of Science ®Google Scholar
• Gabrilovich DI. Myeloid-derived suppressor cells. Cancer Immunol Res. 2017;5(1):3–8.
   PubMed Web of Science ®Google Scholar